Lineage Cell Therapeutics, Inc. Retained Earnings
Lineage Cell Therapeutics, Inc. (LCTX) had Retained Earnings of -$470.33 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$470.33M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$471.81M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$467.00M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$467.85M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$470.33M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | -$471.81M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | -$467.00M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | -$467.85M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | -$438.07M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | -$407.60M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | -$403.46M 10-K · filed 2026-03-05 | |
| 2024-09-30 | -$400.19M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | -$397.16M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | -$391.40M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | -$384.86M 10-K · filed 2025-03-10 | |
| 2023-09-30 | -$380.08M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | -$372.97M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | -$367.74M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | -$363.37M 10-K · filed 2024-03-07 | |
| 2022-09-30 | -$357.02M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | -$350.95M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | -$344.18M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | -$337.10M 10-K · filed 2023-03-09 | |
| 2021-09-30 | -$308.11M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | -$300.28M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | -$295.49M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | -$294.08M 10-K · filed 2022-03-10 | |
| 2020-09-30 | -$296.10M 10-Q · filed 2020-11-04 | |
| 2020-06-30 | -$288.34M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | -$281.82M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | -$273.42M 10-K · filed 2021-03-11 | |
| 2019-09-30 | -$268.94M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | -$252.44M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | -$222.40M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | -$261.86M 10-K · filed 2020-03-12 | |
| 2018-09-30 | -$216.91M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | -$283.63M 10-Q · filed 2018-08-02 | |
| 2018-03-31 | -$279.42M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | -$216.30M 10-K · filed 2019-03-14 | |
| 2017-09-30 | -$144.36M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | -$158.68M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | -$147.03M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | -$196.32M 10-K · filed 2018-03-15 | |
| 2016-09-30 | -$190.53M 10-Q · filed 2016-11-04 | |
| 2016-06-30 | -$221.74M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | -$246.29M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | -$229.89M 10-K · filed 2017-03-16 | -$229.18M 10-K · filed 2016-03-15 |
| 2015-09-30 | -$215.76M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | -$202.06M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | -$192.36M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | -$182.19M 10-K · filed 2016-03-15 | -$182.19M 10-K · filed 2015-03-11 |
| 2014-09-30 | -$171.61M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | -$163.39M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | -$153.88M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | -$145.78M 10-K · filed 2015-03-11 | |
| 2013-09-30 | -$126.17M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | -$117.18M 10-Q · filed 2013-08-09 | |
| 2013-03-31 | -$109.61M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | -$101.90M 10-K · filed 2014-03-17 | |
| 2012-09-30 | -$95.86M 10-Q · filed 2012-11-09 | |
| 2012-06-30 | -$90.90M 10-Q · filed 2012-08-09 | |
| 2012-03-31 | -$85.43M 10-Q · filed 2012-05-10 | |
| 2011-12-31 | -$80.47M 10-K · filed 2013-03-18 | |
| 2011-09-30 | -$75.11M 10-Q · filed 2011-11-08 | |
| 2011-06-30 | -$71.60M 10-Q · filed 2011-08-09 | |
| 2010-12-31 | -$63.95M 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |